Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Humacyte (HUMA) Enterprise Value (2024 - 2025)

Humacyte has reported Enterprise Value over the past 2 years, most recently at -$50.5 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$50.5 million for Q4 2025, down 12.38% from a year ago — trailing twelve months through Dec 2025 was -$50.5 million (down 12.38% YoY), and the annual figure for FY2025 was -$50.5 million, down 12.38%.
  • Enterprise Value for Q4 2025 was -$50.5 million at Humacyte, down from -$19.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for HUMA hit a ceiling of -$19.5 million in Q3 2025 and a floor of -$115.5 million in Q1 2024.